274 related articles for article (PubMed ID: 34780466)
1. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
3. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
5. LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells.
Qin X; Lu M; Zhou Y; Li G; Liu Z
Cell Cycle; 2019 Apr; 18(8):889-897. PubMed ID: 30983519
[TBL] [Abstract][Full Text] [Related]
6. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.
Dana P; Saisomboon S; Kariya R; Okada S; Obchoei S; Sawanyawisuth K; Wongkham C; Pairojkul C; Wongkham S; Vaeteewoottacharn K
Cell Oncol (Dordr); 2020 Apr; 43(2):211-222. PubMed ID: 31729681
[TBL] [Abstract][Full Text] [Related]
7. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
[TBL] [Abstract][Full Text] [Related]
8. miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion.
Zhou Z; Ma J
Cancer Biomark; 2019; 24(2):173-181. PubMed ID: 30594918
[TBL] [Abstract][Full Text] [Related]
9. XB130 promotes proliferation and invasion of gastric cancer cells.
Shi M; Zheng D; Sun L; Wang L; Lin L; Wu Y; Zhou M; Liao W; Liao Y; Zuo Q; Liao W
J Transl Med; 2014 Jan; 12():1. PubMed ID: 24387290
[TBL] [Abstract][Full Text] [Related]
10. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
11. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell.
Xiong GP; Zhang JX; Gu SP; Wu YB; Liu JF
Neoplasma; 2012; 59(4):409-15. PubMed ID: 22489696
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma.
Sang H; Li T; Li H; Liu J
PLoS One; 2013; 8(11):e81347. PubMed ID: 24312291
[TBL] [Abstract][Full Text] [Related]
15. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.
Menakongka A; Suthiphongchai T
World J Gastroenterol; 2010 Feb; 16(6):713-22. PubMed ID: 20135719
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
17. Expression of XB130 in human ductal breast cancer.
Li J; Sun W; Wei H; Wang X; Li H; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):5300-8. PubMed ID: 26191231
[TBL] [Abstract][Full Text] [Related]
18. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
Hu X; Tan Z; Yang Y; Yang P
J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
[TBL] [Abstract][Full Text] [Related]
20. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
Treekitkarnmongkol W; Suthiphongchai T
World J Gastroenterol; 2010 Aug; 16(32):4047-54. PubMed ID: 20731018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
